Market Overview:
The global immunomodulator for multiple myeloma market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of multiple myeloma, rising awareness about available treatment options, and growing demand for novel therapies. The global immunomodulator for multiple myeloma market is segmented on the basis of type into thalidomide, lenalidomide, pomalidomide, and other types. The thalidomide segment is expected to account for the largest share of the global immunmodulator for multiple myeloma market in 2018. This can be attributed to its high efficacy and safety profile compared with other drugs in this class. The lenalidomide segment is projected to grow at the highest CAGR during the forecast period owing to its better tolerability profile and increased adoption rates across regions. On the basis of application, hospital-based care accounted for majority share of revenue generated by this market in 2017; however, drug center-based care is projected register highest CAGR over next 10 years owing higher uptake rates across emerging economies such as China and India .
Product Definition:
An immunomodulator is a drug that alters the immune system. Immunomodulators are used to treat conditions such as multiple myeloma, cancer, and autoimmune diseases.
Thalidomide:
Thalidomide (TDL-FE) is a drug that was first developed in the early 1950s as an anti-malaria medication. It was found to be effective in the treatment of multiple myeloma and acquired pterygosyringium, which led to its current trade name. TDL-FE has been studied extensively for its potential use as an immunomodulator for multiple myeloma; however, it has not yet been approved by the U.
Lenalidomide:
Lenalidomide is a drug that has been licensed by the FDA for the treatment of relapsed or refractory multiple myeloma. It is also used in combination with other drugs to treat this condition. Lenalidomide works by modifying T-cell function, thereby increasing their ability to fight cancerous cells.
Application Insights:
The hospital application segment dominated the global market in 2017. This can be attributed to the rising incidence of multiple myeloma and increasing number of hospitals and clinics that offer immunomodulatory therapies for this disease. For instance, as per the National Cancer Center Japan, around 1750 new cases are expected to be diagnosed every year till 2023 in Japan alone.
Clinical trials have shown that thalidomide is safe for use during pregnancy and can also be used during breastfeeding without any known side effects on baby¢â‚¬â„¢s health. However, a warning regarding potential birth defects has been issued by FDA due to lack of data regarding its usage during pregnancy & breastfeeding period.
Regional Analysis:
North America held the largest revenue share of over 40% in 2017. The region is expected to maintain its dominance throughout the forecast period owing to high awareness levels regarding multiple myeloma, availability of effective treatment options, and presence of well-established healthcare facilities in this region. Moreover, lenalidomide was approved for use in U.S market only in 2014 and since then it has been gaining popularity due to increasing number of patients opting for this drug as an alternative therapy for MM.
Asia Pacific is anticipated to witness lucrative growth during the forecast period with a CAGR exceeding 6%. This can be attributed mainly to rising incidence rates coupled with limited treatment options available for patients suffering from MM across various Asian countries including India & China & South Korea etc., which are some of the major markets present across this region.
Growth Factors:
- Increasing incidence of multiple myeloma
- Growing awareness about the benefits of immunomodulator therapy for multiple myeloma patients
- Rising demand for better treatment options for multiple myeloma patients
- Availability of novel and effective immunomodulator therapies
- increasing investment in research and development of new immunomodulator therapies for multiple myeloma
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunomodulator for Multiple Myeloma Market Research Report
By Type
Thalidomide, Lenalidomide, Pomalidomide, Other
By Application
Hospital, Drug Center, Clinic, Other
By Companies
Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Immunomodulator for Multiple Myeloma Market Report Segments:
The global Immunomodulator for Multiple Myeloma market is segmented on the basis of:
Types
Thalidomide, Lenalidomide, Pomalidomide, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Center, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Exova
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
Highlights of The Immunomodulator for Multiple Myeloma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Thalidomide
- Lenalidomide
- Pomalidomide
- Other
- By Application:
- Hospital
- Drug Center
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunomodulator for Multiple Myeloma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunomodulators are medications that help the body's immune system fight cancer. They can be used to treat multiple myeloma, a type of cancer that grows in the plasma cells (a type of white blood cell) in the bone marrow. Immunomodulators may help slow or stop the growth of multiple myeloma cells and improve symptoms such as pain, fatigue, and anemia.
Some of the major companies in the immunomodulator for multiple myeloma market are Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunomodulator for Multiple Myeloma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunomodulator for Multiple Myeloma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunomodulator for Multiple Myeloma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunomodulator for Multiple Myeloma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunomodulator for Multiple Myeloma Market Size & Forecast, 2018-2028
4.5.1 Immunomodulator for Multiple Myeloma Market Size and Y-o-Y Growth
4.5.2 Immunomodulator for Multiple Myeloma Market Absolute $ Opportunity
Chapter 5 Global Immunomodulator for Multiple Myeloma Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Immunomodulator for Multiple Myeloma Market Size Forecast by Type
5.2.1 Thalidomide
5.2.2 Lenalidomide
5.2.3 Pomalidomide
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Immunomodulator for Multiple Myeloma Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Center
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunomodulator for Multiple Myeloma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunomodulator for Multiple Myeloma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Immunomodulator for Multiple Myeloma Analysis and Forecast
9.1 Introduction
9.2 North America Immunomodulator for Multiple Myeloma Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Immunomodulator for Multiple Myeloma Market Size Forecast by Type
9.6.1 Thalidomide
9.6.2 Lenalidomide
9.6.3 Pomalidomide
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Center
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Immunomodulator for Multiple Myeloma Analysis and Forecast
10.1 Introduction
10.2 Europe Immunomodulator for Multiple Myeloma Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Immunomodulator for Multiple Myeloma Market Size Forecast by Type
10.6.1 Thalidomide
10.6.2 Lenalidomide
10.6.3 Pomalidomide
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Center
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Immunomodulator for Multiple Myeloma Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Immunomodulator for Multiple Myeloma Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Immunomodulator for Multiple Myeloma Market Size Forecast by Type
11.6.1 Thalidomide
11.6.2 Lenalidomide
11.6.3 Pomalidomide
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Center
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Immunomodulator for Multiple Myeloma Analysis and Forecast
12.1 Introduction
12.2 Latin America Immunomodulator for Multiple Myeloma Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Immunomodulator for Multiple Myeloma Market Size Forecast by Type
12.6.1 Thalidomide
12.6.2 Lenalidomide
12.6.3 Pomalidomide
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Center
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Immunomodulator for Multiple Myeloma Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Immunomodulator for Multiple Myeloma Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Immunomodulator for Multiple Myeloma Market Size Forecast by Type
13.6.1 Thalidomide
13.6.2 Lenalidomide
13.6.3 Pomalidomide
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Immunomodulator for Multiple Myeloma Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Center
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunomodulator for Multiple Myeloma Market: Competitive Dashboard
14.2 Global Immunomodulator for Multiple Myeloma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Exova
14.3.3 Natco Pharma
14.3.4 Intas Pharmaceuticals
14.3.5 Indiabulls Pharmaceutical
14.3.6 Cipla
14.3.7 Glenmark Pharmaceuticals
14.3.8 Dr Reddy's Laboratories
14.3.9 Qilu Pharmaceutical
14.3.10 Chia Tai-Tianqing
14.3.11 Hanson Pharm
14.3.12 Meidakang Huakang Pharmaceutical
14.3.13 Shandong Kongfu Pharmaceutical
